Skip To Main Content
US Healthcare Professionals Site

ACTEMRA® (tocilizumab)‎ ALECENSA® (alectinib) Avastin® (bevacizumab) COLUMVI™ (glofitamab-gxbm) COTELLIC® (cobimetinib) ENSPRYNG® (satralizumab-mwge) Erivedge® (vismodegib) Evrysdi® (risdiplam) GAVRETO® (pralsetinib) GAZYVA® (obinutuzumab) HEMLIBRA® (emicizumab-kxwh) Herceptin® (trastuzumab) Herceptin HYLECTA® (trastuzumab and hyaluronidase-oysk) KADCYLA® (ado-trastuzumab emtansine) LUCENTIS® (ranibizumab injection) LUNSUMIO™ (mosunetuzumab-axgb) OCREVUS® (ocrelizumab) PERJETA® (pertuzumab) PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) POLIVY® (polatuzumab vedotin-piiq) Pulmozyme® (dornase alfa) Inhalation Solution Rituxan® (rituximab) for Rheumatoid Arthritis (RA) RITUXAN® (rituximab) for Oncology Rituxan® (rituximab) for Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA) or Pemphigus Vulgaris (PV) RITUXAN HYCELA® (rituximab/hyaluronidase human) ROZLYTREK® (entrectinib) SUSVIMO™ (ranibizumab injection) TECENTRIQ® (atezolizumab) VABYSMO® (faricimab-svoa) VENCLEXTA® (venetoclax tablets) XOLAIR® (omalizumab) for subcutaneous use ZELBORAF® (vemurafenib) Oncology Ophthalmology Rheumatology

ACTEMRA® (tocilizumab)‎ ALECENSA® (alectinib) Avastin® (bevacizumab) COLUMVI™ (glofitamab-gxbm) COTELLIC® (cobimetinib) ENSPRYNG® (satralizumab-mwge) Erivedge® (vismodegib) Evrysdi® (risdiplam) GAVRETO® (pralsetinib) GAZYVA® (obinutuzumab) HEMLIBRA® (emicizumab-kxwh) Herceptin® (trastuzumab) Herceptin HYLECTA® (trastuzumab and hyaluronidase-oysk) KADCYLA® (ado-trastuzumab emtansine) LUCENTIS® (ranibizumab injection) LUNSUMIO™ (mosunetuzumab-axgb) OCREVUS® (ocrelizumab) PERJETA® (pertuzumab) PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) POLIVY® (polatuzumab vedotin-piiq) Pulmozyme® (dornase alfa) Inhalation Solution Rituxan® (rituximab) for Rheumatoid Arthritis (RA) RITUXAN® (rituximab) for Oncology Rituxan® (rituximab) for Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA) or Pemphigus Vulgaris (PV) RITUXAN HYCELA® (rituximab/hyaluronidase human) ROZLYTREK® (entrectinib) SUSVIMO™ (ranibizumab injection) TECENTRIQ® (atezolizumab) VABYSMO® (faricimab-svoa) VENCLEXTA® (venetoclax tablets) XOLAIR® (omalizumab) for subcutaneous use ZELBORAF® (vemurafenib) Oncology Ophthalmology Rheumatology

Your OCREVUS Patient Navigator

Your OCREVUS Patient Navigator is your personal guide during treatment with OCREVUS.

Once you enroll in OCREVUS Access Solutions, you will be teamed up with your own Patient Navigator. This person will work with you and your health care team during your treatment with OCREVUS.

How your Patient Navigator can help

Before your infusion

infusion site

Works with you and your health care provider to find an infusion site

benefits investigation

Walks you through an infusion checklist to help you prepare for treatment

coverage icon

Explains how your insurance can cover your treatment with OCREVUS

financial assistance options

Helps you find financial assistance options, if you are eligible

co-pay program

Explains the OCREVUS Co-pay Program and helps you apply

After your infusion

communications

Is available to answer questions about OCREVUS

phone icon

Reaches out when it's time to prepare for your next infusion

Phone icon

To reach your Patient Navigator at any time during your treatment, call (844) OCREVUS/(844) 627-3887.

Form icon

To enroll in OCREVUS Access Solutions, you must fill out the Patient Consent Form. Your doctor must fill out a different form. We can begin helping you once we receive both these forms.